NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...
The FDA approved a new safety warning for Depo-Provera alerting patients to a possible risk for a type of brain tumor called ...
Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
Pfizer on Thursday formally applied for emergency use authorization with the Food and Drug Administration for a smaller dose of its COVID-19 vaccine for use in children aged between 5 and 11. Thursday ...
US pharma giant Pfizer on Saturday announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...
The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback